Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Feb 6;16(7):670–680. doi: 10.1002/alr.70114

Rationale of New Grading System: Central Compartment Atopic Disease

Ramón Moreno‐Luna 1,2,✉, Carmen Palma‐Martínez 1, Serafin Sánchez‐Gómez 1,2, Isam Alobid 2,3, Daniel Martin‐Jimenez 4,✉, José Miguel Villacampa‐Aubá 5, Christian Calvo‐Henríquez 6, Alfonso Del Cuvillo 7, Alfonso Santamaría‐Gadea 8, Jaime González‐García 1, Richard J Harvey 9, John M DelGaudio 10
PMCID: PMC13326788  PMID: 41649410

ABSTRACT

Background

Central compartment atopic disease (CCAD) has recently been recognized as a distinct phenotype within the spectrum of type 2–dominant chronic rhinosinusitis (CRS). Although international guidelines highlight polypoid changes in the central nasal cavity, standardized diagnostic and classification criteria are still lacking. This study aims to develop and internally validate a consensus‐based classification system through expert agreement.

Methods

A two‐round modified Delphi study was conducted with 10 international rhinology experts. Participants evaluated the need for a specific grading framework, the relative diagnostic value of nasal endoscopy versus radiology, and the clarity and applicability of the proposed criteria (Grades 0–IV). Six representative endoscopic and radiologic cases were used in each round to assess interpretive accuracy and interobserver agreement. Consensus was predefined as ≥ 80% of ratings in the top two categories (4–5) on a 5‐point Likert scale.

Results

Eighty percent of experts identified nasal endoscopy as the primary diagnostic tool in the first Delphi round. The interpretive accuracy of the preliminary grading system was high, with all panelists correctly recognizing the proposed distinctions. Interobserver agreement was substantial (κ = 0.72). In the second round, refined definitions improved overall consensus and reproducibility. Endoscopy was reaffirmed as the cornerstone of diagnosis, while radiology played a complementary role. Diagnostic clarity and agreement increased, reaching κ = 0.80.

Conclusion

The consensus process confirmed nasal endoscopy as the key diagnostic method for CCAD, supported by substantial interobserver reproducibility. The refined definitions improved clarity and agreement, facilitating differentiation from other CRS phenotypes and establishing a reliable framework for future research.

Keywords: Delphi method, nasal polyps, rhinosinusitis, type 2 inflammation

1. Introduction

Chronic rhinosinusitis (CRS) is a heterogeneous disease of the sinonasal mucosa that has traditionally been categorized into two primary phenotypes: CRS without nasal polyps and CRS with nasal polyps (CRSwNP). However, recognition of endotypic and phenotypic variability in recent years has highlighted the limitations of this dichotomy and prompted the identification of new subgroups. Among these, central compartment atopic disease (CCAD) has emerged as a novel phenotype grouped within primary diffuse Type‐2 CRS [1].

First described by DelGaudio et al. in 2017, CCAD refers to polypoid changes of the middle/superior turbinates and posterior septum within an allergic inflammatory continuum [2]. Earlier studies had already linked middle turbinate edema and polypoid changes to inhalant allergy and IgE‐mediated inflammation, supporting CCAD as a distinct nasal inflammatory phenotype strongly associated with aeroallergen exposure and a predominant Type‐2 inflammatory endotype [3, 4, 5].

Subsequent work has confirmed that CCAD exhibits a distinct clinical and pathophysiological profile, characterized by frequent comorbidity with allergic rhinitis, a lower incidence of asthma, and reduced Lund–Mackay scores compared with other Type‐2 subtypes [6]. Notably, marked regional variability has been reported, with differences in clinical expression and inflammatory profiles across China [7], Europe [8, 9], and the United States [10], complicating a unified understanding of the entity. Despite these advances, CCAD remains underrepresented in consensus classifications, and no standardized system exists to guide diagnosis or stratification.

Considering the paucity of evidence on CCAD, endoscopic findings are currently considered the most relevant diagnostic features [11, 12]. Although radiologic patterns and specific clinical characteristics have been described [13], imaging alone remains insufficient for diagnosis and does not obviate the need for endoscopic confirmation. A more comprehensive characterization during endoscopic evaluation is therefore required to ensure consistent identification and strengthen diagnostic accuracy [11]. To address this gap, an international two‐round Delphi study was conducted to develop and validate the first consensus‐based classification system for CCAD, with the aim of improving recognition in clinical practice, guiding individualized management, and providing a standardized framework for future clinical and translational research.

2. Material and Methods

A classification system for CCAD is developed in this work. The systematic protocol followed for its development and validation is shown in detail in Figure 1. The process was based on the hypothesis that a structured staging framework is required to enhance disease understanding, facilitate research, and enable more consistent follow‐up and analysis of this CRS phenotype.

FIGURE 1.

FIGURE 1

Flowchart summarizing the conceptualization, development, and internal Delphi validation of the CCAD grading system, from initial evidence review and single‐center expert evaluation to multicenter pilot rounds and acceptance of the final five grades (0–IV).

2.1. Rationale for Proposing a New Grading System

The rationale for proposing a new grading system for CCAD stems from the need for a structured framework that improves recognition of this phenotype, promotes standardized research, and enables more reliable monitoring of disease progression. Contemporary diagnostic methods are grounded in endoscopic evaluation and aided by imaging, though a consistent staging approach remains absent. Consequently, developing a reproducible system is essential to refine clinical characterization, facilitate longitudinal studies, and provide a foundation for more precise therapeutic decision‐making.

2.2. Participants

The process involved a panel of 10 rhinologists from Europe, the United States, and Australia, all with extensive expertise in CRS diagnosis and management, providing broad geographic and academic representation. All participants had published at least 10 peer‐reviewed articles in JCR‐indexed journals within the past 5 years. The panel included the original descriptors of CCAD and contributors to international consensus efforts such as EPOS 2020, ICAR 2023, and POLINA 2023, ensuring both seniority and methodological rigor in the consensus process. Selection criteria included ≥ 10 years of dedicated clinical experience in the diagnosis and surgical management of CRS; a minimum of five peer‐reviewed publications related to CRS, allergy, or sinonasal inflammatory disease; and regular management of CRS patients, including at least 50 endoscopic sinus surgeries per year. Participation was voluntary, anonymous, and conducted via electronic surveys. Each iteration of the proposed framework was systematically cross‐checked and validated by senior international experts (J.D. and R.H.), the original descriptors of the entity, ensuring methodological rigor and validation.

2.3. Delphi Process

A modified two‐round Delphi consensus approach was employed to develop and validate a novel grading system for CCAD. In the first round, participants were asked to reach a preliminary consensus on the need for a CCAD‐specific classification, the relative diagnostic value of nasal endoscopy versus radiology, and the clarity and applicability of the proposed grading criteria (Grades 0–IV), including radiologic subclassifications based on the Lund–Mackay (L–M) scale [14]. Experts were also invited to evaluate the diagnostic and interpretative capacity of the system when applied to representative clinical cases (Supporting Information S1). To structure this assessment, three domains were evaluated: (1) need for classification, including six questions on its clinical value, the relevance of diagnostic tools (i.e., endoscopy and radiology), and diagnostic agreement on representative images; (2) interpretative accuracy, with six items assessing the ability to distinguish between the proposed grades; and (3) interobserver agreement, using six clinical cases presented as images or endoscopic video sequences for classification.

The second round focused on refining and validating the preliminary framework (Supporting Information S2). Experts re‐evaluated the proposed grading criteria in light of group feedback, confirmed nasal endoscopy as the main diagnostic criterion and radiologic subclassifications as complementary information, and assessed the reproducibility and clinical applicability of the system across different practice settings. Particular emphasis was placed on the system's ability to stratify disease severity, guide individualized management, and provide a standardized research tool.

The Delphi exercise was conceived as an internal validation of the CCAD grading concept, primarily focused on face and content validity. In line with methodological guidance for vignette‐based Delphi designs, a limited number of carefully selected clinical scenarios spanning the full spectrum of disease were used to minimize respondent fatigue and allow repeated rating and detailed qualitative feedback. Six index cases covering CCAD Grades 0–IV and typical borderline presentations were selected, and each case was independently graded by 10 rhinologists in two rounds, yielding 120 individual ratings in total. No formal a priori sample‐size calculation was performed for the number of cases and ratings, as Delphi consensus studies typically rely on purposive expert sampling, and no reliable effect size for agreement was available beforehand. Instead, a post hoc precision and power analysis under a binomial model was conducted using a predefined consensus threshold of ≥ 80% agreement and a significance level of α = 0.05; this analysis confirmed that the ratings provided adequate precision for estimating agreement.

Criteria for defining agreement among rhinologists in both rounds were established a priori. Thus, consensus was defined as ≥ 80% of panelists rating 4–5 on a 5‐point Likert scale, with ≤ 15% rating 1–2. Items with 70%–79% agreement were considered near‐consensus and refined for re‐evaluation, whereas < 70% was regarded as non‐consensus.

2.4. Statistical Analysis

For Likert‐scale items [1, 2, 3, 4, 5], descriptive statistics were summarized as median and interquartile range (IQR), and the proportion of top‐2 box responses (Ratings 4–5), representing the percentage of experts expressing high agreement, was calculated to quantify agreement and positive consensus level. 95% confidence intervals (CI) for these proportions were derived using the Wilson method, which provides accurate interval estimates for binomial data [15, 16]. Stability between rounds was defined as an absolute change < 10% points in the top‐2 box proportion combined with an IQR ≤ 1, indicating consistent responses across rounds.

Interobserver agreement for clinical case classifications (Grades 0–IV) was then tested using weighted Fleiss’ κ with quadratic weighting, which measures the level of agreement among multiple raters while accounting for the ordinal nature of the grading scale [17]. A total of 95% CI for κ estimates were obtained through non‐parametric bootstrap with 1000 iterations to ensure robust interval estimation [18].

To assess the robustness of interobserver agreement, sensitivity analyses were performed using Gwet's AC2 coefficient, an alternative reliability index for ordinal variables that accounts for potential prevalence or distribution bias [19, 20]. Kendall's W, which measures concordance of ranked data, was not applied due to it being highly sensitive to ties and unsuitable for categorical agreement in this context [21, 22].

3. Results

3.1. First Round

In the first Delphi round, consensus was reached regarding diagnostic priorities. Most experts (> 80%) prioritized nasal endoscopy as the main CCAD diagnostic tool, while only 10% favored radiology assessment. When two representative videos were evaluated, 90% of participants correctly recognized the CCAD case and 80% accurately identified the eosinophilic CRS (eCRS) case, demonstrating strong agreement in the initial diagnostic evaluation. Interpretative accuracy was also high, as all participants (100%) correctly identified the theoretical grade distinctions proposed in the initial classification, indicating a high level of interpretative accuracy and consistent understanding of the grading definitions.

Importantly, consensus was also reached on the hierarchical role of diagnostic modalities.

Interobserver agreement for clinical cases in this first round is detailed in Table 1. Agreement was high in most examples, particularly for classic presentations such as typical middle turbinate polyps (Case 4, 80%) and advanced polyposis (Case 5, 100%). By contrast, borderline cases (i.e., Case 3, 50%; Case 6, 70%) showed greater variability, mainly between Grades 2 and 3.

TABLE 1.

Results of the first round.

Case Most frequent classification Agreement level Observations
1 Grade 1A (90%) High High diagnostic clarity
2 Grade 3A (90%) High 10% overestimated grade
3 Grade 2A (50%) Moderate Variability between Grades 2 and 3
4 Grade 2 (80%) High Typical middle turbinate polyps
5 Grade 4B (100%) Very high Clear extensive polyposis
6 Grade 3A (70%) Moderate Some dispersion toward 2A/1B in subtle cases

Note: From a statistical perspective, interobserver reliability was substantial, with a weighted Fleiss’ κ of 0.72 (95% CI, 0.64–0.79). Likert items showed a median of 5 (IQR 1), and the proportion of top‐2 box responses was 80% (95% CI, 74%–86%).

3.2. Second Round

The refined classification framework was applied after providing corrections derived from the first round, which improved consensus across most dimensions. Agreement on diagnostic priorities was reinforced, reflecting 90% expert consensus and confirming nasal endoscopy as the main diagnostic tool. In contrast, the radiologic image was considered complementary. In addition, interpretative accuracy remained strong, with improved consistency in distinguishing grades. Cases that had been previously ambiguous, such as borderline polyps, were more consistently classified after revision.

Interobserver agreement improved notably (Table 2). Typical CCAD presentations, such as Grade 2 disease (Case 3, 100%), achieved complete consensus, while diffuse polyposis with sinus extension (Case 4, 90%) and advanced phenotypes (Case 5, 90%) also showed very high reproducibility. Some residual variability was observed in Case 1 (80%), though clarity improved compared to the first round.

TABLE 2.

Results of the second round.

Case Most frequent classification Agreement level Observations
1 Grade 3A (80%) High More dispersion compared to the first round (previously 1A)
2 Grade 4A (80%) High Adjacent polyps, possible underestimation
3 Grade 2 (100%) Very high Classic presentation, exemplary case
4 Grade 4B (90%) Very high Advanced presentation with sinus extension
5 Grade 3A (90%) Very high Accurate polyp localization
6 Grade 1A (90%) High Some difficulty distinguishing edema versus early polyp

Note: Results of the second Delphi round for the LOEM classification system. The table summarizes the most frequent classification assigned to each case, the percentage of agreement among panelists, and key qualitative observations derived from the experts’ comments. Agreement levels were categorized as very high (≥ 90%) and high (≥ 80%).

In addition, under a simple binomial model, analysis of the 120 individual ratings (10 experts × 6 cases × 2 rounds) demonstrated robust agreement estimates, with top‐2 box proportions of 80% in the first round (95% CI, 74%–86%) and 88% in the second round (95% CI, 83%–92%). With this sample size, statistical power to discriminate an agreement level of 80% from a conservative null hypothesis of 60% exceeded 99% at α = 0.05, indicating that the observed consensus levels were both highly precise and strongly discriminative.

3.3. Round‐to‐Round Stability and Statistical Outcomes

Reliability between rounds improved, with weighted Fleiss’ κ increasing to 0.80 (95%CI, 0.73–0.86). Likert‐scale items maintained a median of 5 (IQR 0–1), and the proportion of top‐2 box responses rose to 88% (95%CI, 83%–92%). Stability criteria were fulfilled, showing absolute changes < 10 percentage points across all items. Sensitivity analyses using Gwet's AC2 confirmed consistent results (range 0.78–0.85) (Table 3).

TABLE 3.

Delphi consensus results across two rounds.

Round Median % agreement IQR Average % agreement Weighted Fleiss’ κ (95% CI) Top‐2 box % (95% CI)
First 85.0% 17.5 80.0% 0.72 (0.64–0.79) 80% (74%–86%)
Second 90.0% 7.5 88.3% 0.80 (0.73–0.86) 88% (83%–92%)

Note: Interobserver reliability was assessed using weighted Fleiss’ κ with 95% confidence intervals. “Top‐2 box” agreement refers to the proportion of cases where ≥ 80% of experts selected either the first or second most frequent classification, a common metric in Delphi methodology. Improvement from Round 1 to Round 2 reflects iterative refinement of the grading system.

Abbreviation: IQR, interquartile range.

Diagnostic accuracy and interobserver agreement improved between rounds, particularly for typical CCAD phenotypes (Grades 2, 3A, and 4B). Ambiguous cases became clearer after refinement, while borderline situations continued to show some variability. Overall, these results reinforce the role of endoscopy as the cornerstone of CCAD assessment, with radiology serving a complementary role.

3.4. New Grading System for CCAD

The Delphi process resulted in the development of a consensus‐based endoscopic classification system for CCAD. In this system, Grade 0 corresponds to a normal central compartment, while Grades I–IV represent progressive stages of endoscopic involvement (Supporting Information S3) as described below:

  • Grade 1: Endoscopically characterized by edema of the middle turbinate and/or the superior‐posterior nasal septum, without polyp formation. The middle meatus and the remainder of the nasal cavity appear normal.

  • Grade 2: Endoscopically characterized by the presence of small polyps arising from the middle turbinate (involving its head, body, tail, or lateral surface) or from the superior turbinate. The middle meatus and the rest of the nasal cavity remain normal.

  • Grade 3: Endoscopically characterized by polyps located medial to the middle turbinate, typically originating from the superior‐posterior nasal septum, with or without concomitant edema or polyps at the middle or superior turbinate (as in Grade 2). The middle meatus and other nasal regions remain unaffected.

  • Grade 4: Endoscopically characterized by any of the above grades of CCAD coexisting with diffuse CRSwNP not otherwise (NOS).

    • −

      Small: Polyps arising from the middle meatus and extending at least to, but not beyond, the dorsum of the inferior turbinate.

    • −

      Large: Polyps arising from the middle meatus and extending below the dorsum of the inferior turbinate, indicating greater obstruction and inflammatory burden.

The classification is further complemented by radiologic subclassifications based on the L–M score (0–2) (Supporting Information S3).

Endoscopy was validated as the cornerstone of diagnosis, with radiologic imaging serving a complementary role in selected contexts. The proposed scale reliably distinguishes localized CCAD from diffuse CRSwNP not otherwise specified (CRSwNP‐NOS), demonstrates strong interobserver agreement, and provides a reproducible framework for patient stratification in both clinical practice and future research.

4. Discussion

This study presents the first structured classification of CCAD, primarily grounded in endoscopic findings. Through a two‐round Delphi consensus, endoscopy was validated as the cornerstone of diagnosis, while imaging proved useful as complementary information in selected cases. Refinement of the grading system also led to a more reliable distinction between localized CCAD and CRSwNP‐NOS, achieving strong diagnostic accuracy and substantial interobserver agreement. This refined framework enhanced diagnostic consistency and supported more precise phenotyping of patients with central compartment involvement.

Primarily, the Delphi results (Tables 1 and 2) underscored the importance of CCAD as a distinct phenotype (evidenced by consensus on a dedicated classification) and demonstrated the feasibility of implementing a reproducible grading scale across different settings. The iterative refinement of definitions between Delphi rounds translated into improved interobserver agreement, supporting the robustness of the final system. This iterative process constitutes an internal validation of the CCAD grading system, confirming its reproducibility and reliability among experts. Future studies should focus on prospective validation in independent patient cohorts.

Comparison with existing CRS classifications highlights the added value of this system. Current frameworks, such as EPOS [1] and ICAR [23], rely on a dichotomous distinction between presence or absence of nasal polyps, with eCRS often serving as a modifier. However, these schemes do not adequately encompass the central compartment phenotype, despite mounting evidence of its distinct immunopathological profile. By establishing objective, reproducible endoscopic criteria complemented by radiological nuances, the proposed CCAD grading system addresses this gap, providing clinicians and researchers with a tool to more precisely delineate disease subtypes.

From a clinical standpoint, a standardized CCAD classification is essential to improve recognition and avoid misclassification under the broader CRSwNP umbrella. The proposed grading system provides a framework that not only facilitates early recognition of CCAD but also supports stage‐specific management strategies. In CCAD, the combination of symptomatology and endoscopic findings may help guide stage‐specific management, supporting a more tailored therapeutic approach according to disease severity. In cases of discordance between endoscopic and radiologic findings, the endoscopic grade was defined as the determinant for CCAD classification. Given that CCAD is fundamentally an endoscopically defined entity [2, 11], nasal endoscopy was considered the primary diagnostic modality, while radiologic findings were regarded as complementary. Accordingly, when discrepancies arose between endoscopic staging and radiologic extent, grading was assigned based on endoscopic assessment, with imaging findings recorded as additional contextual or subclassification information. This rule was predefined to ensure consistency in grading and to reflect the central role of direct mucosal evaluation in the diagnosis of CCAD.

In a Grade 0, patients without edema or polyps in the central compartment serve as a negative reference, ensuring that CCAD is not overdiagnosed. This baseline emphasizes the specificity of the classification in distinguishing CCAD from other CRS phenotypes.

Importantly, Grade 1, defined by turbinate edema without polyp formation (Figure 2), likely represents the earliest manifestation of CCAD, strongly linked to allergic sensitization and type 2 inflammation [4, 24].

FIGURE 2.

FIGURE 2

Grade 1, endoscopy visualization. MT, middle turbinate; NS, nasal septum. Visual summary aims to facilitate understanding and ensure consistent interpretation of the classification.

On the other hand, patients with Grade 2, characterized by localized polypoid degeneration of the middle turbinate, represent a predominantly allergic phenotype with greater disease burden (Figure 3). Clinical studies confirm the close association between CCAD, allergy, and asthma [8], highlighting a challenging clinical situation, supporting consideration of immunotherapy in conjunction with medical management to assess its potential implications [25]. Closer follow‐up is advisable, as these patients may be at higher risk of disease progression despite conservative treatment [26], and their identification could underscore the timing of intervention to be explored in future studies. In Grade 2 of this new classification, we do not stratify polyp size, as the key diagnostic feature is their origin from the middle or superior turbinate—structures closely linked to allergic inflammation in CCAD. The phenotypic relevance lies in their location within the central compartment, not in their dimensional extent. Prior studies have shown that isolated middle turbinate polypoid changes are strongly associated with atopy [27], and even middle turbinate edema alone (Grade 1) may serve as a clinical marker of inhalant allergy [4]. While future studies may explore correlations with nasal airflow or symptom burden, the current grading system prioritizes endoscopic and anatomic phenotypes over other features.

FIGURE 3.

FIGURE 3

Grade 2, endoscopy visualization. IT, inferior turbinate; MT, middle turbinate; NS, nasal septum; UP; Uncinate process. *Polyps. Visual summary aims to facilitate understanding and ensure consistent interpretation of the classification.

In applying the grading system, borderline cases may occasionally arise that do not clearly fit a single grade. Conversely, if only edema is present without discrete polyps, the case should be considered Grade 1. Likewise, if standard endoscopic visualization of the central compartment is limited (for instance, due to prior surgery or anatomical variants), characteristic radiologic findings (central compartment mucosal changes on imaging) can assist in classification, although endoscopic confirmation remains the diagnostic gold standard whenever feasible.

Comorbid atopy represents a central and highly characteristic feature of the CCAD phenotype and should be actively assessed in patients with suspected disease. A history of inhalant allergy and/or positive allergy testing provides strong supportive evidence for CCAD and reinforces its distinction from other CRS phenotypes. Nevertheless, allergy cannot be considered a mandatory diagnostic criterion. A subset of patients demonstrates typical CCAD endoscopic features in the absence of systemic IgE sensitization, a finding that may reflect local IgE production within the sinonasal mucosa or alternative type 2 inflammatory pathways. This observation is consistent with recent reports indicating that, while evidence of allergy is highly suggestive of CCAD, negative allergy testing does not exclude the diagnosis. Accordingly, in the proposed grading framework, endoscopic findings constitute the defining diagnostic criterion, whereas comorbid atopy is regarded as an important adjunctive feature that supports phenotyping and may have therapeutic implications, rather than an absolute requirement for diagnosis [4, 6].

In patients with prior sinonasal surgery or significant anatomical variants, interpretation of the Lund–Mackay score may be confounded by postoperative changes or altered sinus ventilation. In such cases, grading of CCAD should rely primarily on endoscopic findings, with radiologic subclassification applied cautiously or omitted when imaging does not reliably reflect active disease. Radiologic findings may provide supportive information, particularly when endoscopic visualization of the central compartment is limited; however, imaging should not independently alter the endoscopic grade. This approach preserves the endoscopy‐based nature of the classification while allowing flexibility in complex postoperative scenarios.

Grade 3, marked by posterior septal polyps with or without concomitant turbinate involvement, reflects a greater inflammatory load (Figure 4). Previous reports have shown that CCAD patients with advanced endoscopic involvement often require surgical intervention, with outcomes comparable or superior to other CRSwNP phenotypes [10, 28]. Recognizing and characterizing this progression offers the opportunity for a more tailored therapeutic strategy, grounded in a deeper understanding of the underlying inflammatory mechanisms and the extent of surgical intervention.

FIGURE 4.

FIGURE 4

Grade 3, endoscopy visualization. MT, middle turbinate; NS, nasal septum. *Polyps. Visual summary aims to facilitate understanding and ensure consistent interpretation of the classification.

Finally, Grade 4, which combines CCAD features with diffuse sinonasal polyposis involving the paranasal sinuses (CRSwNP‐NOS), represents a challenging mixed CRS phenotype (Figure 5). Clinical outcome data indicate that these patients frequently benefit from endoscopic sinus surgery [28], whereas biologic therapy may be considered in severe or refractory cases. This underscores the importance of accurate identification and a clearly defined management strategy for this subgroup [10, 28]. Recognizing this grade is essential to avoid misclassification under diffuse CRSwNP and to ensure individualized, multidisciplinary care. In contrast to CRSwNP‐NOS, which typically reflects diffuse inflammatory disease driven by combined mechanical and immunologic factors, CCAD is characterized by a localized, aeroallergen‐driven type 2 inflammatory response confined to the central compartment of the nasal cavity, with secondary sinus involvement due to obstruction. This distinction is clinically relevant for both prognosis and therapeutic tailoring. It is important to recognize that Grade 4 is not a further progression from Grade 3, but represents the co‐existence of CCAD and CRSwNP‐NOS.

FIGURE 5.

FIGURE 5

Grade 4, endoscopy visualization. MT, middle turbinate; NS, nasal septum. *Polyps. Visual summary aims to facilitate understanding and ensure consistent interpretation of the classification.

4.1. Limitations

This study has several limitations. First, the Delphi panel included only 10 rhinologists, all with subspecialty expertise, which may limit generalizability to broader clinical practice. Second, while internal reliability was demonstrated, the proposed classification has not yet been prospectively validated in patient cohorts, and its predictive value for clinical outcomes (e.g., surgical success or response to biologic or allergen immunotherapy) remains undetermined; likewise, biomarker and endotype data were not integrated into this study, which may underrepresent the biological heterogeneity of CCAD.

The limited scope of the index cases represents an inherent limitation of this initial Delphi‐based validation. However, a post hoc precision and power analysis based on the 120 individual ratings demonstrated that the agreement estimates were statistically robust and sufficiently precise. Despite these encouraging findings, multicenter studies involving larger and more heterogeneous real‐world cohorts are required to externally validate the proposed CCAD grading scale and to confirm its generalizability across diverse clinical settings.

External validation remains a critical next step. Our group is actively planning multicenter prospective studies to test the reproducibility of this classification in independent patient cohorts, to correlate grades with biomarkers and patient‐reported outcomes, and to assess its prognostic utility for guiding therapeutic strategies. These ongoing efforts will be essential to confirm generalizability and to determine the prognostic and therapeutic value of the CCAD grading system.

5. Conclusion

This consensus‐based CCAD classification provides the first reproducible and internationally validated framework for recognizing and staging this phenotype. Diagnostic accuracy and interobserver agreement improved through iterative refinement, particularly for typical CCAD presentations, confirming endoscopy as the cornerstone of diagnosis and radiology as a complementary tool. By linking endoscopic features to stage‐specific management, the scale may help address a gap in CRS phenotyping and support future evaluation, so CCAD is not overlooked within the broader CRSwNP spectrum.

Funding

The authors have nothing to report.

Conflicts of Interest

The authors declare no conflicts of interest.

Supporting information

Supporting File 1:alr70114‐sup‐0001‐SupMat.docx

ALR-16-670-s001.docx (2.2MB, docx)

Acknowledgments

The authors are deeply grateful to the international panel of rhinologists and CRS specialists who generously contributed their expertise, time, and critical feedback during the Delphi method consensus rounds. Their engagement and constructive discussion were instrumental in refining definitions, ensuring methodological rigor, and validating the proposed classification.

Moreno‐Luna R., Palma‐Martínez C., Sánchez‐Gómez S., et al. “Rationale of New Grading System: Central Compartment Atopic Disease.” International Forum of Allergy & Rhinology 16, no. 7 (2026): 670–680. 10.1002/alr.70114

Richard J. Harvey and John M. DelGaudio served as senior authors.

Contributor Information

Ramón Moreno‐Luna, Email: ramoluorl@gmail.com.

Daniel Martin‐Jimenez, Email: dmartin0701@gmail.com.

References

  • 1. Fokkens W. J., Lund V. J., Hopkins C., et al., “European Position Paper on Rhinosinusitis and Nasal Polyps 2020,” Rhinology 58, no. S29 (2020): 1–464. [DOI] [PubMed] [Google Scholar]
  • 2. DelGaudio J. M., Loftus P. A., Hamizan A. W., Harvey R. J., and Wise S. K., “Central Compartment Atopic Disease,” American Journal of Rhinology and Allergy 31, no. 4 (2017): 228–234. [DOI] [PubMed] [Google Scholar]
  • 3. Orlandi R. R., Kingdom T. T., Smith T. L., et al., “International Consensus Statement on Allergy and Rhinology: Rhinosinusitis 2021,” International Forum of Allergy and Rhinology 11, no. 3 (2021): 213–739. [DOI] [PubMed] [Google Scholar]
  • 4. Hamizan A. W., Christensen J. M., Ebenzer J., et al., “Middle Turbinate Edema as a Diagnostic Marker of Inhalant Allergy,” International Forum of Allergy and Rhinology 7, no. 1 (2017): 37–42. [DOI] [PubMed] [Google Scholar]
  • 5. White L. J., Rotella M. R., and DelGaudio J. M., “Polypoid Changes of the Middle Turbinate as an Indicator of Atopic Disease,” International Forum of Allergy and Rhinology 4, no. 5 (2014): 376–380. [DOI] [PubMed] [Google Scholar]
  • 6. Lin Y. T., Lin C. F., Liao C. K., Chiang B. L., and Yeh T. H., “Clinical Characteristics and Cytokine Profiles of Central‐Compartment‐Type Chronic Rhinosinusitis,” International Forum of Allergy and Rhinology 11, no. 7 (2021): 1064–1073. [DOI] [PubMed] [Google Scholar]
  • 7. Nie Z., Xu Z., Fan Y., et al., “Clinical Characteristics of Central Compartment Atopic Disease in Southern China,” International Forum of Allergy and Rhinology 13, no. 3 (2023): 205–215. [DOI] [PubMed] [Google Scholar]
  • 8. Marcus S., Schertzer J., Roland L. T., Wise S. K., Levy J. M., and DelGaudio J. M., “Central Compartment Atopic Disease: Prevalence of Allergy and Asthma Compared With Other Subtypes of Chronic Rhinosinusitis With Nasal Polyps,” International Forum of Allergy and Rhinology 10, no. 2 (2020): 183–189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Luna R. M., Melgar J. V., Jiménez D. M., Comes M. C., Cossio P. I., and Gómez S. S., “Diagnostic Challenges of Central Compartment Atopic Disease in Type‐2 Chronic Rhinosinusitis,” Acta Otorrinolaringologica Espanola (forthcoming). [DOI] [PubMed] [Google Scholar]
  • 10. Steehler A. J., Vuncannon J. R., Wise S. K., and DelGaudio J. M., “Central Compartment Atopic Disease: Outcomes Compared With Other Subtypes of Chronic Rhinosinusitis With Nasal Polyps,” International Forum of Allergy and Rhinology 11, no. 11 (2021): 1549–1556. [DOI] [PubMed] [Google Scholar]
  • 11. Barrow E. M., Wise S. K., Botros A., Harvey R. J., Edwards T. S., and DelGaudio J., “Central Compartment Atopic Disease: Analysis of Current Literature and Proposal of Diagnostic Criteria,” International Forum of Allergy and Rhinology 15, no. 10 (2025): 1113–1135. [DOI] [PubMed] [Google Scholar]
  • 12. Vizcarra‐Melgar J., Moreno‐Luna R., Martín‐Jiménez D., et al., “Phenotypic Features of Central Compartment Atopic Disease Compared With Other Types of Chronic Rhinosinusitis: A Systematic Review,” Current Allergy and Asthma Reports 25, no. 1 (2025): 43. [DOI] [PubMed] [Google Scholar]
  • 13. Abdullah B., Vengathajalam S., Md Daud M. K., Wan Mohammad Z., Hamizan A., and Husain S., “The Clinical and Radiological Characterizations of the Allergic Phenotype of Chronic Rhinosinusitis With Nasal Polyps,” Journal of Asthma and Allergy 13 (2020): 523–531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Lund V. J. and Mackay I. S., “Staging in Rhinosinusitis,” Rhinology 31, no. 4 (1993): 183–184. [PubMed] [Google Scholar]
  • 15. Newcombe R. G., “Two‐Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods,” Statistics in Medicine 17, no. 8 (1998): 857–872. [DOI] [PubMed] [Google Scholar]
  • 16. Wilson E. B., “Probable Inference, the Law of Succession, and Statistical Inference,” Journal of the American Statistical Association 22, no. 158 (1927): 209–212. [Google Scholar]
  • 17. Fleiss J., “Measuring Nominal Scale Agreement Among Many Raters,” Psychological Bulletin 76 (1971): 378–382. [Google Scholar]
  • 18. Efron B. and Tibshirani R. J., An Introduction to the Bootstrap, 1st ed. (Chapman and Hall/CRC, 1994), 456. [Google Scholar]
  • 19. Wongpakaran N., Wongpakaran T., Wedding D., and Gwet K. L., “A Comparison of Cohen's Kappa and Gwet's AC1 When Calculating Inter‐Rater Reliability Coefficients: A Study Conducted With Personality Disorder Samples,” BMC Medical Research Methodology 13 (2013): 61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Gwet K. L., “Computing Inter‐Rater Reliability and Its Variance in the Presence of High Agreement,” British Journal of Mathematical and Statistical Psychology 61, no. 1 (2008): 29–48. [DOI] [PubMed] [Google Scholar]
  • 21. Legendre P., “Species Associations: The Kendall Coefficient of Concordance Revisited,” Journal of Agricultural, Biological, and Environmental Statistics 10, no. 2 (2005): 226–245. [Google Scholar]
  • 22. Kendall M. G. and Smith B. B., “The Problem of m Rankings,” Annals of Mathematical Statistics 10, no. 3 (1939): 275–287. [Google Scholar]
  • 23. Wise S. K., Damask C., Roland L. T., et al., “International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis 2023,” International Forum of Allergy and Rhinology 13, no. 4 (2023): 293–859. [DOI] [PubMed] [Google Scholar]
  • 24. Rubel K. E., Lubner R. J., Lopez A. A., et al., “Inflammatory Characteristics of Central Compartment Atopic Disease,” International Forum of Allergy and Rhinology 13, no. 12 (2023): 2133–2143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Meerwein C. M., Sacks P. L., Ho J., et al., “The Effect of Allergen Immunotherapy in Patients With Central Compartment Atopic Disease Post‐Surgery,” International Forum of Allergy and Rhinology 15, no. 2 (2025): 128–134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Edwards T. S., DelGaudio J. M., Levy J. M., and Wise S. K., “A Prospective Analysis of Systemic and Local Aeroallergen Sensitivity in Central Compartment Atopic Disease,” Otolaryngology–Head and Neck Surgery 167, no. 5 (2022): 885–890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. DelGaudio J. M., “Middle Turbinate Resection May Lead to Nasal Septal Polyp Formation in Allergic Patients,” International Forum of Allergy and Rhinology 15, no. 10 (2025): 1178–1180. [DOI] [PubMed] [Google Scholar]
  • 28. DelGaudio J. M., Levy J. M., and Wise S. K., “Central Compartment Involvement in Aspirin‐Exacerbated respiratory Disease: The Role of Allergy and Previous Sinus Surgery,” International Forum of Allergy and Rhinology 9, no. 9 (2019): 1017–1022. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting File 1:alr70114‐sup‐0001‐SupMat.docx

ALR-16-670-s001.docx (2.2MB, docx)

Articles from International Forum of Allergy & Rhinology are provided here courtesy of Wiley

RESOURCES